Inverness
This article was originally published in The Tan Sheet
Executive Summary
June launch of Clearblue digital pregancy test to be followed by digital ovulation test next year, CEO Ron Zwanziger says at UBS Global Life Sciences Conference Sept. 23 (1"The Tan Sheet" Aug. 4, 2003, p. 9). Fifteen-second ad spots for Clearblue digital pregnancy test began airing on network TV Sept. 15, are slated to break on cable TV in October, he states. Tagline "if only everything in life were this clear," created by Christian, Baum and Bond (New York), targets women ages 25-36. "It is too early to say how sales [of the product] are doing, but we have seen encouraging early results," Zwanziger notes, predicting Inverness Medical Innovations revenues will reach $275 mil. in FY 2003...
You may also be interested in...
Inverness Expands Home Pregnancy Market Share With Fact Plus Acquisition
Inverness Medical Innovations will immediately take over distribution of Abbott Labs' Fact plus OTC home pregnancy tests after acquiring the line along with several professional test kit products from the firm in a $92.5 mil. deal
Inverness Building Consumer Product Sales, Has High Hopes For Clearblue
Consumer products contributed roughly three-quarters of Inverness Medical Innovations' $65.7 mil. second quarter net revenues, the firm reported in a July 31 earnings call
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.